Pfizer, Inc. · NYSE:PFE
Pfizer — 44th Annual J.P. Morgan Healthcare Conference 2026
8 slides from Pfizer's conference presentation, January 2026
Slide 1: Pfizer Investor Overview at 2026 J.P. Morgan Healthcare Conference
Pfizer Investor Overview At 2026 J.P. Morgan Healthcare Conference January 2026 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward - Looking Statements and Non - GAAP Financial Information • Our discussions during this presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such st
Slide 3: 2026 Strategic Priorities
202 6 Strategic Priorities • Maximize value of key transactions • Deliver on critical R&D milestones • Invest to maximize post-2028 growth • Scale AI across our business 3
Slide 4: 2026 Revenue Guidance
2026 Revenue Guidance 1 2025 Guidance2 2026 Guidance1 Reported Revenues ~$62.0B $59.5 – $62.5B (midpoint $61.0B) COVID-19 Products ~$6.5B ~$5.0B 2026 LOE Impact1 ~$(1.5B) Operational Growth Excluding COVID and LOE ~ 4% Products 2026 Revenues (at the midpoint) excluding COVID and LOEs expected to gro
Slide 5: 2026 Guidance: Other Components
2026 Guidance 1: Other Components Reported Revenues $59.5 to $62.5 Billion Adjusted1 SI&A Expenses $12.5 to $13.5 Billion Adjusted1 R&D Expenses $10.5 to $11.5 Billion Effective Tax Rate on Adjusted1 Income Approximately 15.0% Adjusted1 Diluted EPS $2.80 to $3.00 1. See slide 8 for definitions, incl
Slide 6: Delivering Operating Margin Expansion through Productivity Gains
Delivering Operating Margin Expansion through Productivity Gains Significant progress driving operational efficiency throughout our business 2024 2025 2026 2027 Total Phase 1 Manufacturing $0.6B $0.7B $0.2B Optimization Program $1.5B Cost Realignment Program1 $5.1B $0.6B $5.7B $29.7B 2 $24.1B 3 $24.
Slide 7: Pfizer Pipeline | Key Anticipated 2026 Catalysts
Pfizer Pipeline |Key Anticipated 202 6 Catalysts Regulatory Decisions Data Readouts Pivotal Study Starts HYMPAVZI (marstacimab) ELREXFIO (elranatamab) HYMPAVZI (marstacimab) PD-1xVEGF (PF’4404) Hemophilia A/B with Inhibitors Double-class Exposed Relapsed / Refractory Multiple Myeloma Moderate Hemoph
Slide 8: Footnotes
Footnotes (1) Adjusted income and Adjusted diluted earnings per share (EPS) are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain ac
Pfizer — 44th Annual J.P. Morgan Healthcare Conference 2026 on 6ix